Anna Stanton

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

Paul Griffiths, Anna Stanton, Erin McCarrell et al. · The Lancet · 2011 · 397 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Simeng Lin, Nicholas A. Kennedy, Aamir Saifuddin et al. · Nature Communications · 2022 · 81 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres

Mark Samaan, Polychronis Pavlidis, Emma Johnston et al. · Frontline Gastroenterology · 2016 · 51 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy

Paul Griffiths, Emily S. Rothwell, Mohammed Raza et al. · PLoS ONE · 2016 · 41 citations · Full text

Veterinary Medicine, Infectious Diseases, Infectious Disease Pharmacotherapy +12

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Zhigang Liu, Kaixing Le, Xin Zhou et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 35 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17